CJC-1295 research guide for Bulskamp. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Research-Grade CJC-1295 for Bulskamp Investigators
For anyone in Bulskamp trying to locate CJC-1295, the first thing to know is that this compound is distributed via specialist online vendors. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor controls every quality variable. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. The sections below cover what Bulskamp researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Bulskamp researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors begins with the COA: locate the batch-specific certificate prior to buying, not after. The HPLC analytical chromatogram is the most important document in the COA: it should show a large primary peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be 98% or higher. For Bulskamp researchers evaluating new suppliers: a small initial order to verify quality before scaling up your order is the accepted approach among experienced researchers. For Bulskamp researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Bulskamp
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no discount compensates for this missing data. PubMed and related preprint servers are the primary literature resources for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
